Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 99.08M P/E - EPS this Y 42.10% Ern Qtrly Grth -
Income -177.08M Forward P/E -0.76 EPS next Y 19.00% 50D Avg Chg -9.00%
Sales 93.16M PEG 0.21 EPS past 5Y - 200D Avg Chg -70.00%
Dividend N/A Price/Book 0.41 EPS next 5Y -7.30% 52W High Chg -90.00%
Recommedations 2.80 Quick Ratio 4.78 Shares Outstanding 184.08M 52W Low Chg 3.00%
Insider Own 1.06% ROA -20.16% Shares Float 154.66M Beta 0.60
Inst Own 73.93% ROE -128.02% Shares Shorted/Prior 7.76M/8.47M Price 0.52
Gross Margin 59.22% Profit Margin -190.09% Avg. Volume 3,442,837 Target Price 2.65
Oper. Margin -155.33% Earnings Date Nov 5 Volume 1,328,463 Change 0.58%
About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics News
11/18/24 Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
11/10/24 Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
11/09/24 Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/08/24 Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
11/08/24 Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
11/07/24 Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Nektar: Q3 Earnings Snapshot
11/07/24 Nektar Therapeutics Reports Third Quarter 2024 Financial Results
11/07/24 Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/06/24 Nektar Therapeutics to Participate in Upcoming Investor Conferences
11/05/24 Nektar Therapeutics to sell Alabama facility to Ampersand
11/04/24 Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
11/04/24 Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
10/31/24 Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
10/29/24 Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
10/17/24 Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
09/25/24 Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
09/11/24 Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
09/03/24 Nektar Management to Present at Upcoming Investor Conferences
08/13/24 What Makes Nektar (NKTR) a New Buy Stock
NKTR Chatroom

User Image breakoutstock Posted - 4 hours ago

$NKTR I bought at $1.02

User Image BK217 Posted - 5 hours ago

$NKTR dizzzzamm! Broke through a buck! Womp womp. Thank God for conviction and liquidity!

User Image PercyFinn Posted - 6 hours ago

$NKTR NKTR-255 in combination with durvalumab findings from phase 2 Rescue study.👍 https://www.onclive.com/view/dr-lin-on-the-safety-of-nktr-255-in-enhancing-immune-recovery-post-chemoradiation-in-locally-advanced-nsclc

User Image breakoutstock Posted - 14 hours ago

$XCUR told you a long time ago. Been holding since $1.90 the same will happen to $NKTR

User Image Elena_Graves Posted - 1 day ago

$RIGL $OMER $NKTR LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image PLATINUM_TRADES Posted - 1 day ago

$NKTR wouldn't look bad if it wasn't for that shelf offering that came out I less I'm mistaken. If one can hold should make a move.. Has to hold

User Image Hastein Posted - 1 day ago

$NKTR When do you think the adr mediation between Nektar and Lilly will end? I think the news will come out on November 27, 2024 or January 9, 2025. Waiting for new. Keep buying. I add 5000 shares. That's good price!!

User Image BK217 Posted - 2 days ago

$NKTR will probably touch 0.90 or a tad lower before any turnaround

User Image Hastein Posted - 2 days ago

$NKTR buy in the dip. Add more.

User Image Bulltrader988 Posted - 3 days ago

$NKTR todays presentation https://www.nektar.com/wp-content/uploads/2024/11/NKTR-422_Saul-Kivimae_Nektar_final18NOV24.pdf

User Image Bug1 Posted - 3 days ago

$NKTR we need back tictok posts or chatgpt dd.. that would lift us!

User Image georgeyann Posted - 3 days ago

$NKTR add 2k shares

User Image breakoutstock Posted - 3 days ago

$NKTR buying on the open

User Image Bulltrader988 Posted - 5 days ago

$NKTR 13G 14.11.2024 Eventide Asset Management acquired 9,400,000 shares https://www.sec.gov/Archives/edgar/data/1442891/000158064224006950/eventide_nektar-sc13g.htm

User Image BK217 Posted - 5 days ago

$NKTR now own 861,716 at 0.59 basis Looking forward to getting above 1M on this weakness

User Image Shorttermtrade Posted - 5 days ago

$NKTR Can anyone explain the reason for the sell off Is LLY settlement at risk and the insiders know something that we dont

User Image Hastein Posted - 5 days ago

$NKTR add more 7000 shares 1.08

User Image investorTim Posted - 6 days ago

$NKTR long term hold

User Image breakoutstock Posted - 6 days ago

$NKTR buying

User Image Hastein Posted - 6 days ago

$NKTR good price. Add more

User Image Biotech_Beast Posted - 6 days ago

$NKTR I've gone from hold to buy on my rating of this name. There is a run of catalysts ahead. https://seekingalpha.com/article/4737301-multiple-catalysts-ahead-for-nektar-therapeutics

User Image PercyFinn Posted - 6 days ago

$NKTR Someone reached a panic sell button again.

User Image ktrader1991 Posted - 1 week ago

$NKTR tang loves lung cancer related companies. He might be sniffing around.

User Image BK217 Posted - 1 week ago

$NKTR more short covering 2nd half of Oct…shares sold short at 10/15 decreased by 800k to 5.2m, down from 6m at 10/31 and down from 9.7m at 7/15 Steady demand for short covering but not much else. Seems like the calm before the storm

User Image Winning_calls Posted - 1 week ago

$NKTR pick me up @ $1.43 😉

User Image Bulltrader988 Posted - 1 week ago

$NKTR nice one❗❗

User Image Bug1 Posted - 1 week ago

$NKTR https://www.targetedonc.com/view/nktr-255-shows-promise-for-reversing-radiation-induced-lymphopenia-in-nsclc

User Image Bulltrader988 Posted - 1 week ago

$NKTR and this also very interesting next week(s): ""Next week, we are looking forward to presenting highly promising data at the 2024 ACR Convergence Meeting for our preclinical PEG-CSF program, NKTR-422." Presentation is on Monday, November 18, 2024 3:15 PM – 3:30 PM Eastern Time https://acr24.eventscribe.net/fsPopup.asp?efp=WERIVEhVR0kxOTQ4MQ&PresenterID=1950884&rnd=0.2564075&mode=presenterinfo

User Image Bulltrader988 Posted - 1 week ago

$NKTR beginning next week ❗❗

User Image breakoutstock Posted - 1 week ago

$NKTR I’m hearing chatter

Analyst Ratings
Jefferies Hold Mar 6, 24
TD Cowen Outperform Nov 9, 23
Mizuho Neutral Aug 7, 23
Jefferies Hold May 10, 23
Oppenheimer Perform Mar 6, 23
Goldman Sachs Sell Feb 27, 23
SVB Leerink Market Perform Feb 24, 23
Jefferies Underperform Feb 24, 23
JP Morgan Underweight Aug 8, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Nov 17 Sell 0.49 9,646 4,727 274,039 11/20/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Nov 17 Sell 0.49 7,179 3,518 243,780 11/20/23
ROBIN HOWARD W President & CEO President & CEO Nov 17 Sell 0.49 19,877 9,740 899,922 11/20/23
Curet Myriam Director Director Sep 18 Sell 0.69 4,359 3,008 27,418 09/20/23
CHESS ROBERT Director Director Sep 18 Sell 0.67 10,200 6,834 274,773 09/20/23
Ajer Jeffrey Robert Director Director Sep 18 Sell 0.69 4,359 3,008 34,153 09/20/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 16 Sell 0.78 9,703 7,568 283,685 08/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Aug 16 Sell 0.78 7,221 5,632 250,959 08/17/23
ROBIN HOWARD W President & CEO President & CEO Aug 16 Sell 0.78 19,998 15,598 919,799 08/17/23
WHITFIELD ROY A Director Director Jun 14 Sell 0.57 30,000 17,100 216,250 06/15/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer May 16 Sell 0.72 9,791 7,050 293,388 05/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer May 16 Sell 0.72 7,543 5,431 257,680 05/17/23
ROBIN HOWARD W President & CEO President & CEO May 16 Sell 0.72 20,361 14,660 939,797 05/17/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Feb 16 Sell 3.00 10,484 31,452 303,179 02/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Feb 16 Sell 3.00 8,275 24,825 265,223 02/17/23
Thomsen Jillian B. Chief Financial Offi.. Chief Financial Officer Feb 16 Sell 3.00 10,267 30,801 313,497 02/17/23
ROBIN HOWARD W President & CEO President & CEO Feb 16 Sell 3.00 19,635 58,905 960,158 02/17/23
Curet Myriam Director Director Sep 23 Sell 3.16 4,198 13,266 31,777 09/26/22
Ajer Jeffrey Robert Director Director Sep 23 Sell 3.16 4,198 13,266 38,512 09/26/22
CHESS ROBERT Director Director Sep 22 Sell 3.19 5,100 16,269 228,179 09/26/22
EASTHAM KARIN Director Director Sep 13 Sell 3.61 21,267 76,774 13,033 09/14/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 18 Sell 4.65 73,716 342,779 327,123 08/19/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 15 Sell 4.76 10,560 50,266 400,839 08/17/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Aug 15 Sell 4.76 3,189 15,180 281,188 08/17/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Aug 15 Sell 4.76 2,006 9,549 334,859 08/17/22
ROBIN HOWARD W President & CEO President & CEO Aug 15 Sell 4.76 13,759 65,493 1,017,807 08/17/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer May 15 Sell 3.95 21,673 85,608 276,399 05/17/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel May 16 Sell 3.95 3,136 12,387 117,939 05/17/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer May 15 Sell 3.95 5,841 23,072 170,427 05/17/22
ROBIN HOWARD W President & CEO President & CEO May 15 Sell 3.95 36,529 144,290 620,941 05/17/22
NORTHCOTT JOHN SVP & Chief Commerci.. SVP & Chief Commercial Officer May 16 Sell 3.95 4,592 18,138 223,210 05/17/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO May 15 Sell 3.95 17,448 68,920 312,905 05/17/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Feb 16 Sell 10.95 10,912 119,486 274,122 02/18/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 16 Sell 10.95 3,661 40,088 121,075 02/18/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Feb 16 Sell 10.95 2,363 25,875 165,318 02/18/22
ROBIN HOWARD W President & CEO President & CEO Feb 16 Sell 10.95 12,480 136,656 589,020 02/18/22
NORTHCOTT JOHN SVP & Chief Commerci.. SVP & Chief Commercial Officer Feb 16 Sell 10.95 4,852 53,129 227,802 02/18/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 16 Sell 10.95 7,579 82,990 301,603 02/18/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Aug 18 Sell 13.7 10,867 148,878 240,231 08/18/21
CHESS ROBERT Director Director Apr 16 Option 13.8 8,000 110,400 288,573 04/16/21
CHESS ROBERT Director Director Apr 16 Sell 18.98 8,000 151,840 280,573 04/16/21
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 04 Option 8.8 5,344 47,027 84,244 02/04/21
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 04 Sell 19.45 5,344 103,941 78,900 02/04/21
ROBIN HOWARD W President & CEO President & CEO Feb 04 Option 8.8 450,000 3,960,000 608,693 02/04/21
ROBIN HOWARD W President & CEO President & CEO Feb 04 Sell 20.42 450,000 9,189,000 458,693 02/04/21
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 04 Option 8.8 150,000 1,320,000 316,973 02/04/21
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 04 Sell 20.4 150,000 3,060,000 266,973 02/04/21
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Jan 29 Option 8.8 75,000 660,000 251,257 01/29/21
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Jan 29 Sell 18.62 75,000 1,396,500 176,257 01/29/21